These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25926246)

  • 41. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal.
    Vieira T; de Oliveira JF; da Graça Castel-Branco M
    Allergol Immunopathol (Madr); 2014; 42(1):3-10. PubMed ID: 23253691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real life study of three years omalizumab in patients with difficult-to-control asthma.
    López Tiro JJ; Contreras EA; del Pozo ME; Gómez Vera J; Larenas Linnemann D
    Allergol Immunopathol (Madr); 2015; 43(2):120-6. PubMed ID: 24780091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
    Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma.
    Tat TS; Cilli A
    Ann Allergy Asthma Immunol; 2016 Nov; 117(5):546-549. PubMed ID: 27788886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
    Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
    Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.
    Colombo GL; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Bruno GM; Pitotti C; Menzella F
    Ther Adv Respir Dis; 2019; 13():1753466619841350. PubMed ID: 31035904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Omalizumab response in patients with asthma by number and type of allergen.
    Soong W; Yoo B; Pazwash H; Holweg CTJ; Casale TB
    Ann Allergy Asthma Immunol; 2021 Aug; 127(2):223-231. PubMed ID: 33838339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland.
    Subramaniam A; Al-Alawi M; Hamad S; O'Callaghan J; Lane SJ
    QJM; 2013 Jul; 106(7):631-4. PubMed ID: 23550166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
    Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
    Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
    Apsangikar P; Ghadge P; Naik M; Nair S
    J Assoc Physicians India; 2020 Dec; 68(12):61-65. PubMed ID: 33247645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
    Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
    J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Quality of life in patients with allergic asthma on treatment with omalizumab].
    Aguilar-Hinojosa NK; Sánchez-Tec G
    Rev Alerg Mex; 2018; 65(4):349-356. PubMed ID: 30602204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.